The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

Shares of IO Biotech, Inc. IOBT are plummeting Tuesday after the company announced it filed for Chapter 7 bankruptcy and will ...

Alumis Inc., a San Francisco-based biotech, completed its IPO in June last year, raising ~$250m, and focuses on developing TYK2 inhibitors ESK-001 and A-005. Alumis' ESK-001 is in Phase 3 trials for ...